Question for written answer E-002816/2022
to the Commission
Rule 138
Peter Jahr (PPE)


A number of cosmetics companies – mostly SMEs – are developing and producing eyelash serum, among other products. Eyelash serum as a cosmetic product has been on the market for 12 years now, with no confirmed serious undesirable effects (SUEs). As no concerns about the product have yet been raised, no data on its ingredients (e.g. prostaglandins) are available. The Commission asked the Scientific Committee on Consumer Safety (SCCS) to arrange for a study to be carried out on prostaglandins, one of the ingredients used in eyelash serum. The Commission has access to those product safety assessments.

1. What is the Commission’s position on SCCS opinion 1635/21, in particular as regards the uncertainties regarding the selection and assessment of SUEs?

2. What scientific knowledge and what knowledge about SUEs are based on possible regulatory measures, especially given that the wording ‘cannot be excluded’ appears overly vague?

3. As part of the decision-making process, the Commission is requesting further studies and test results from manufacturers on the effects and side effects of prostaglandin derivatives. How will the results of the data collection feed into the decision-making process, and how transparent will it be for the companies concerned?